Respiratory syncytial virus

Viral Infections and Treatment

Volumn , Issue , 2016, Pages 91-137

  Wyde, Philip R ^a   Piedra, Pedro A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 15244345289     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14823-6     Document Type: Chapter

References (244)

1. McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields B, Knipe DM, Chanock RM, Hirsch MS, Melnick JL, Monath TP, Roizman B, eds. Fields Virology. New York: Raven Press, 1990: 1045-1074.
2. McIntosh K. Respiratory syncytial virus infections in infants and children:diagnosis and treatment. Pediatr Res 1987; 9:191-196.
3. Hall CB. Respiratory syncytial virus. In: Feigin RD, Cherry JD, eds. Textbook of Paediatric Infectious Diseases. Philadelphia: W.B. Saunders, 1998: 2084-2111.
4. Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, Piedra PA. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999; 103:619-626.
5. Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 1999; 179:25-30.
6. Whimbey E, Ghosh S. Respiratory syncytial virus infections in immunocompromised adults. Curr Clin Topics Infect Dis 2000; 20:232-255.
7. Hall CB. Respiratory syncytial virus: a continuing culprit and conundrum. J Pediatr 1999; 135:S2-S7.
8. La Via WV, Marks MI, Stutman HR. Respiratory syncytial virus puzzle:clinical features, pathophysiology, treatment and prevention. J Pediatr 1992; 121:503-510.
9. Bont L, van Aalderen WMC, Kimpen JLL. Long-term consequences of respiratory syncytial virus RSV bronchiolitis. Paediatr Respir Rev 2000; 1:221-227.
10. Lenney W. RSV disease-is there a role for prevention? Resp Med 2001; 95:170-172.
11. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13. Lancet 1999; 354:541-545.
12. Noble V, Murray M, Webb MSC, Alexander J, Swarbrick AS, Milner AD. Respiratory status and allergy 9 to 10 years after acute bronchiolitis. Arch Dis Child 1997; 76:315-319.
13. Levy BT, Graber MA. Respiratory syncytial viral infections in infants and young children. J Fam Pract 1997; 45:73-81.
14. Stang P, Brandenburg N, Carter B. The economic burden of respiratory syncytial virus-associated bronchiolitis hospitalizations. Arch Pediatr Adolesc Med 2001; 155:95-96.
15. Howard TS, Hoffman LH, Stang PE, Simoes EA. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges and mortality. J Pediatr 2000; 137:227-232.
16. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 2001; 282:1440-1446.
17. National Respiratory and Enteric Virus Surveillance System collaborating laboratories. Respiratory syncytial virus activity-United States, 1999-2000 season. MMWR 2001; 49:1091-1092.
18. Stott EJ, Taylor G, Jebbett J, Collins AP. The characterisation and uses of monoclonal antibodies to respiratory syncytial virus. Dev Biol Stand 1984; 57:237-244.
19. Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF, Stone Y, McIntosh K. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 1985; 151:626-633.
20. Mufson MA, Belshe RB, Orvell C, Norrby E. Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children. J Infect Dis 1988; 157:143-148.
21. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991; 163:693-698.
22. Hall CB, Douglas RG. Modes of transmission of respiratory syncytial virus. J Pediatr 1981; 99:100-103.
23. Swedish Consensus Group. Management of infections caused by respiratory syncytial virus. Scand J Infect Dis 2001; 33:323-328.
24. Sims DG, Downham MAPS, Webb KG, Gardner PS, Weightman D. Hospital cross-infection on children’s wards with respiratory syncytial virus and the role of adult carriage. Acta Paediatr Scand 1975; 64:541-545.
25. Hart RJC. An outbreak of respiratory syncytial virus infection in an old people’s home. J Infect 1984; 8:259-261.
26. Collins PL, McIntosh K, Chanock RM. Respiratory syncytial virus. In:Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE, eds. Fields Virology. Philadelphia: Lippincott-Raven, 1996: 1313-1352.
27. Hardy RW, Wertz GW. The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J Virol 1998; 72:520-526.
28. Collins PL, Hill MG, Cristina J, Grosfeld H. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proc Natl Acad Sci USA 1996; 93:81-85.
29. Atreya PL, Kulkarni S. Respiratory syncytial virus strain A2 is resistant to the antiviral effects of type I interferons and human MxA. Virology 1999; 261:227-241.
30. Bolt G, Pedersen LO, Birkeslund HH. Cleavage of the respiratory syncytial virus fusion protein is required for its surface expression: role of furin. Virus Res 2000; 68:25-33.
31. Horvath CM, Lamb RA. Studies on the fusion peptide of a paramyxovirus fusion glycoprotein: roles of conserved residues in cell fusion. J Virol 1992; 66:2443-2445.
32. Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, Melero J. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 1992; 73:2225-2234.
33. Johnson PR, Sprigg MK, Olmsted RA, Collins PL. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci USA 1987; 84:5625-5629.
34. Sullender WM, Mufson MA, Anderson LJ, Wertz GW. Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. J Virol 1991; 65:5425-5434.
35. Sanz MC, Kew OM, Anderson LJ. Genetic heterogeneity of the attachment glycoprotein G among group A respiratory syncytial viruses. Virus Res 1994; 33:203-217.
36. Collins PL, Mottet G. Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A. J Gen Virol 1992; 73:849-863.
37. Tebbey PW, Hagen M, Hancock GE. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment G protein of respiratory syncytial virus. J Exp Med 1998; 188:1967-1972.
38. Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, Clements-Mann ML, Harris DO, Randolph VB, Udem SA, Murphy BR, Sidhu MS. Respiratory syncytial virus RSV. SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci USA 1997; 94:13961-13966.
39. Feldman SA, Hendry RM, Beeler JA. Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol 1999; 73:6610-6617.
40. Martinez I, Melero JA. Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. J Gen Virol 2000; 81:2715-2722.
41. Norrby E, Marusyk H, Orvell C. Ultrastructural studies of the multiplication of RS respiratory syncytial virus. Acta Pathol Microbiol Scand 1970; 78):268.
42. Gardner PS, McQuillan J, Court SD. Speculation on pathogenesis in death from respiratory syncytial virus infection. Br Med J 1970; 1:327-330.
43. Aherne W, Bird T, Court SDM, Gardner PS, McQuillin J. Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 1970; 23:7-18.
44. Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 1999; 340:260-264.
45. McIntosh K. Respiratory viral infections. In: Pizzo PA, Wilfert CM, eds. Pediatric AIDS. The Challenge of HIV Infection in Infants, Children and Adolescents. Baltimore: Williams & Wilkins, 1994: 365-376.
46. Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingston, 2000:1782-1801.
47. Krilov LR. Respiratory syncytial virus: update on infection, treatment and prevention. Curr Infect Dis Rep 2001; 3:242-246.
48. Selwyn BJ. The epidemiology of acute respiratory tract infection in young children. Res Infect Dis 1990; 12:5870-5888.
49. Glezen WP, Paredes A, Allison JE, Taber LH. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group and maternal antibody level. Pediatrics 1981; 98:708-715.
50. Welliver RC, Kaul A, Ogra PL. Cell-mediated immune response to respiratory syncytial virus infection: relationship to the development of reactive airway disease. J Pediatr 1979; 94:370-375.
51. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000; 161:1501-1507.
52. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. Br Med J 1993; 307:982-986.
53. Johnston SL. Viruses and asthma. Allergy 1998; 53:922-932.
54. Ogra PL. From chimpanzee coryza to palivizumab: changing times for respiratory syncytial virus. Pediatr Infect Dis J 2000; 19:774-779.
55. Welliver RC, Ogra PL. RSV, IgE, and wheezing. J Pediatr 2001; 139:903-904.
56. Garofalo R, Kimpen JL, Welliver RC, Ogra PL. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr 1992; 120:28-32.
57. Olszewska-Pazdrak B, Pazdrak K, Ogra PL, Garofalo RP. Respiratory syncytial virus-infected pulmonary epithelial cells induce eosinophil degranulation by a CD18-mediated mechanism. J Immunol 1998; 160:4889-4895.
58. Everard ML, Swarbrick A, Wrightham M, Mcintyre J, Dunkley C, James PD, Sewell HF, Milner AD. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child 1994; 71:428-432.
59. Busse WW, Lemanske RF. Advances in immunology: asthma. N Engl J Med 2001; 344:350-361.
60. Castro M, Chaplin DD, Walter MJ, Holtzman MJ. Could asthma be worsened by stimulating the T-helper type 1 immune response? Am J Resp Cell Mol Biol 2000; 22:143-146.
61. de Alarcon A, Walsh EE, Carper HT, La Russa JB, Evans BA, Rakes GP, Platts-Mills TAE, Heymann PW. Detection of IgA and IgG but not IgE antibody to respiratory syncytial virus in nasal washes and sera from infants with wheezing. J Pediatr 2001; 138:311-317.
62. Collins PL, Chanock RM, McIntosh K. Parainfluenza viruses. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE, eds. Fields Virology. Philadelphia: Lippincott-Raven, 1996: 1205-1242.
63. Jackson M, Scott R. Different patterns of cytokine induction in cultures of respiratory syncytial RS-virus-specific human Th cell lines following stimulation with RS virus and RS virus proteins. J Med Virol 1996; 49:161-169.
64. Srikiatkhachorn A, Braciale TJ. Virus-specific CD8þ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 1997; 186:421-432.
65. Hussell T, Openshaw PJM. Intracellular IFN-gamma expression in natural killer cells precedes lung CD8þ T cell recruitment during respiratory syncytial virus infection. J Gen Virol 1998; 79:2593-2601.
66. Johnson TR, Graham BS. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 IL-5, IL-13, and eosinophilia by an IL-4- independent mechanism. J Virol 1999; 73:8485-8495.
67. Tripp RA, Moore D, Jones L, Sullender W, Winter J, Anderson LJ. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol 1999; 73:7099-7107.
68. Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenzalike illness: an observational study. Lancet 2001; 358:1410-1416.
69. Krilov LR, Lipson SM, Barone SR, Kaplan MH, Ciamician Z, Harkness SH. Evaluation of a rapid diagnostic test for respiratory syncytial virus RSV:potential for bedside diagnosis. Pediatrics 1994; 93:903-906.
70. Paton AW, Paton JC, Lawrence AJ, Goldwater PN, Harris RJ. Rapid detection of respiratory syncytial virus in nasopharyngeal aspirates by reverse transcription and polymerase chain reaction amplification. J Clin Microbiol 1992; 30:901-904.
71. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969; 89:449-463.
72. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiological study of altered clinical reactivity to respiratory syncytial RS virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-421.
73. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrot RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-434.
74. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:435-438.
75. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, Rodriguez WJ, Chanock RM. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986; 24:197-202.
76. Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion-glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988; 26:1595-1597.
77. Alwan WH, Kozlowska WJ, Openshaw PJM. Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med 1994; 179:81-89.
78. Tripp RA, Moore D, Anderson LJ. Th-1- and Th-2-type cytokine expression by activated T lymphocytes from the lung and spleen during the inflammatory response to respiratory syncytial virus. Cytokine 2000; 12:801-807.
79. Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC, Sotnikov AV, Murphy BR. Pulmonary histopathology induced by respiratory syncytial virus RSV challenge of formalin-inactivated RSV-immunized Balb/c mice is abrogated by depletion of CD4þ T cells. J Virol 1992; 66:7444-7451.
80. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996; 70:2852-2860.
81. Boelen A, Andeweg A, Kwakkel J, Lokhorst W, Bestebroer T, Dormans J, Kimman T. Both immunisation with a formalin-inactivated respiratory syncytial virus RSV vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine 2000; 19:982-991.
82. Kahn JS. Respiratory syncytial virus vaccine development. Curr Opin Pediatr 2000; 12:257-262.
83. Nadal D, Ogra PL. Development of local immunity: role in mechanisms of protection against or pathogenesis of respiratory syncytial viral infection. Lung Suppl 1990; 168:379-387.
84. Oien NL, Brideau RJ, Walsh EE, Wathen MW. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin b subunit. Vaccine 1994; 12:731-735.
85. Hu K-F, Ekstrom J, Merza M, Lovgren-Bengtsson K, Morein B. Induction of antibody responses in the common mucosal immune system by respiratory syncytial virus immunostimulating complexes. Med Microbiol Immunol 1999; 187:191-198.
86. Groothuis JR. Role of antibody and use of respiratory syncytial virus RSV immune globulin to prevent severe RSV disease in high-risk children. J Pediatr 1994; 124:S28-S32.
87. Anderson LJ, Heilman CA. Protective and disease-enhancing immune responses to respiratory syncytial virus. J Infect Dis 1995; 171:1-7.
88. Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 1998; 177:463-466.
89. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, Tristam DA, Siber GR, Prince GA, Van Raden M, Hemming VG, and the Respiratory Syncytial Virus Immune Globulin Study Group. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993; 329:1524-1530.
90. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-537.
91. Cox RA, Rao P, Brandon-Cox C. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit. J Hosp Infect 2001; 48:186-192.
92. Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1976; 134:211-217.
93. Brandenburg AH, Groen J, van Steensel-Moll HA, Claas EC, Rothbarth PH, Neijens HJ, Osterhaas AD. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 1997; 52:97-104.
94. Osterhaus ADME, Devries P, Vanbinnendijk RS. Measles vaccines: novel generations and new strategies. J Infect Dis 1994; 170:S42-S55.
95. Bui RHD, Molinaro GA, Kettering JD, Heiner DC, Imagawa DT, St Geme JW Jr. Virus-specific IgE and IgG4 antibodies in serum of children infected with respiratory syncytial virus. J Pediatr 1987; 100:87-90.
96. Rabatic S, Gagro A, Lokar-Kolbas R, Krsulovic-Hresic V, Vrtar Z, Popow-Kraupp T, Drazenovic V, Mlinaric-Galinovic G. Increase in CD23þ. B cells in infants with bronchiolitis is accompanied by appearance of IgE and IgG4 antibodies specific for respiratory syncytial virus. J Infect Dis 1997; 175:32-37.
97. Bangham CR, McMichael AJ. Specific human cytotoxic T cells recognize Bcell lines persistently infected with respiratory syncytial virus. Proc Natl Acad Sci USA 1986; 83:9183-9187.
98. Mbawuike IN, Wells J, Byrd R, Cron SG, Glezen WP, Piedra PA. HLArestricted CD8þ cytotoxic T lymphocyte, interferon- gamma, and interleukin-4 responses to respiratory syncytial virus infection in infants and children. J Infect Dis 2001; 183:687-696.
99. Bangham CRM, Cannon MJ, Karzon DT, Askonas BA. Cytotoxic T-cell response to respiratory syncytial virus in mice. J Virol 1985; 56:55-59.
100. Gupta R, Yewdell JW, Olmsted RA, Collins PL, Bennink JR. Primary pulmonary murine cytotoxic T lymphocyte specificity in respiratory syncytial virus pneumonia. Microb Pathol 1990; 9:13-18.
101. Nicholas JA, Rubino KL, Levely ME, Meyer AL, Collins PL. Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus RSV is associated with a significant reduction in pulmonary RSV replication. Virology 1991; 182:664-672.
102. Munoz JL, McCarthy CA, Clark ME, Hall CB. Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virusspecific cytotoxic T cells. J Virol 1991; 65:4494-4497.
103. Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cellmediated immunity. J Pediatr 1980; 96:179-186.
104. Chakrabarti S, Collingham KE, Marshall T, Holder K, Gentle T, Hale G, Fegan CD, Milligan DW. Respiratory virus infections in adult T celldepleted transplant recipients: the role of cellular immunity. Transplant 2001; 72:1460-1463.
105. Cannon MJ, Openshaw PJM, Askonas BA. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988; 168:1163-1168.
106. Alwan WH, Record FM, Openshaw PJM. CD4þ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8þ T cells. Clin Exp Immunol 1992; 88:527-236.
107. Brandenburg AH, Kleinjan A, Land BV, Moll HA, Timmerman HH, deSwart RL, Neijens HJ, Fokkens W, Osterhaus ADME. A type 1-like immune response is found in children with respiratory syncytial virus infection regardless of clinical severity. J Med Virol 2000; 62:267-277.
108. Hall CB, Douglas RG Jr, Simons RL, Geiman JM. Interferon production in children with respiratory syncytial virus, influenza, and parainfluenza virus infections. J Pediatr 1978; 93:28-32.
109. Roman M, Calhoun WJ, Hinton KL, Avendano LF, Simon V, Escobar AM, Gaggero ADPV. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am J Respir Crit Care Med 1997; 156:190-195.
110. Bendelja K, Gagro A, Bace A, Lokar-Kolbas R, Krsulovic-Hresic V, Drazenovic V, Mlinaric-Galinovic G, Rabatic S. Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry. Clin Exp Immunol 2000; 121:332-338.
111. Crowe JE Jr. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus RSV and parainfluenza virus PIV. Vaccine 1995; 13:415-421.
112. Pringle CR, Filipiuk AH, Robinson BS, Watt PJ, Higgins P, Tyrrell DA. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine 1993; 11:473-478.
113. Crowe JE Jr, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR. Cold passaged, temperature-sensitive mutants of human respiratory syncytial virus RSV are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 1995; 13:847-855.
114. Karron R, Wright P, Crowe J Jr, Clements-Mann M, Thompson J, Makhene M, Casey R, Murphy B. Evaluation of two live, cold-passaged, temperature- sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults. J Infect Dis 1997; 176:1428-1436.
115. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331-1342.
116. Teng MN, Whitehead SS, Bermingham A, StClaire M, Elkins WR, Murphy BR, Collins PL. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 2000; 74:9317-9321.
117. Jin H, Cheng X, Zhou H, Li S, Seddiqui A. Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene M2-2 has altered growth characteristics and is attenuated in rodents. J Virol 2000; 74:74-82.
118. Collins PL, Whitehead SS, Bukreyev A, Fearns R, Teng MN, Juhasz K, Chanock RM, Murphy BR. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res 1999; 54:423-451.
119. Bukreyev A, Whitehead SS, Bukreyeva N, Murphy BR, Collins PL. Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity. Proc Natl Acad Sci USA 1999; 96:2367-2372.
120. Connors M, Collins PL, Firestone C-Y, Murphy BR. Respiratory syncytial virus RSV F, G, M2 22K, and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively shortlived. J Virol 1991; 65:1634-1637.
121. Du RP, Jackson GED, Wyde PR, Yan WY, Wang QJ, Gisonni L, Sanhueza SE, Klein MH, Ewasyshyn ME. A prototype recombinant vaccine against respiratory syncytial virus and parainfluenza virus type 3. Biotechnology 1994; 12:813-818.
122. Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. Recombinant bovine/ human parainfluenza virus type 3 B/HPIV3 expressing the respiratory syncytial virus RSV G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol 2001; 75:4594-4603.
123. Mason HS, Warzecha H, Mor T, Arntzen CJ. Edible plant vaccines:applications for prophylactic and therapeutic molecular medicine. Trends Mol Med 2002; 8:324-329.
124. Korban SS, Krasnyanski SF, Buetow DE. Foods as production and delivery vehicles for human vaccines 2002; J Am Coll Nutr 21:212S-217S.
125. Sandu JS, Krasnyanski SF, Domier LL, Korban SS, Osadjan MD, Buetow DE. Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response. Transgenic Res 2000; 9:127-135.
126. Piedra PA, Glezen WP, Kasel JA, Welliver RC, Jewel AM, Rayford Y, Hogerman DA, Hildreth SW, Paradiso PR. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Vaccine 1995; 13:1095-1101.
127. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. Safety and immunogenicity of a purified F protein respiratory syncytial virus PFP-2 vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 1998; 177:467-469.
128. Piedra PA, Grace S, Jewell A, Spinelli S, Bunting D, Hogerman DA, Malinoski F, and Hiatt PW. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 1996; 15:23-31.
129. Falsey A, Walsh E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine PFP-2 in ambulatory adults over age 60. Vaccine 1996; 145:1214-1218.
130. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine PFP-2 in the institutionalized elderly. Vaccine 1997; 15:1130-1132.
131. Simoes EAF, Tan DHS, Ohlsson A, Sales V, Wang EEL. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine 2001; 20:954-960.
132. Goetsch L, Plotnicky-Gilquin H, Aubry JP, De-Lys P, Haeuw JF, Bonnefoy JY, Nguyen NT, Corvaia N, Velin D. BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against virus challenge after nasal immunization in mice. Vaccine 2001; 19:4036-4043.
133. Bastien N, Trudel M, Simard C. Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine 1999; 17:832-836.
134. Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Stahl S, Uhlen M, Nguyen TN, Binz H. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 1997; 230:155-166.
135. Dagouassat N, Robillard V, Haeuw JF, PlotnickyGilquin H, Power UF, Corvaia N, Nguyen T, Bonnefoy JY, Beck A. A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine. Vaccine 2001; 19:4143-4152.
136. Power UF, Nguyen TN, Rietveld E, deSwart RL, Groen J, Osterhaus ADME, deGroot R, Corvaia N, Beck A, Bouveretle-Le-Cam N, Bonnefoy JY. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 2001; 184:1456-1460.
137. Simmons CP, Hussell T, Sparer T, Walzl G, Openshaw P, Dougan G. Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8þ T cell responses. J Immunol 2001; 166:1106-1113.
138. Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, Chanock RM, Murphy BR, Clements-Mann ML, Falsey AR. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine PFP-2 in healthy young and older adults. Vaccine 2000; 18:1763-1772.
139. Hancock GE, Smith JD, Heers KM. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12. Viral Immunol 2000; 13:57-72.
140. Connors M, Collins PL, Firestone C-Y, Sotnikov AV, Waitze A, Davis AR, Hung PP, Chanock RM, Murphy BR. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 1992; 7:475-484.
141. Li XM, Sambhara S, Li CX, Ewasyshyn M, Parrington M, Caterini J, James O, Cates G, Du RP, Klein M. Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med 1998; 188:681-688.
142. Andersson C, Liljestrom P, Stahl S, Power UF. Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunisation encoding a secreted RSV G protein-derived antigen. FEMS Immunol Med Microbiol 2000; 29:247-253.
143. Bembridge GP, Rodriguez N, Garcia-Beato R, Nicolson C, Melero JA, Taylor G. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J Gen Virol 2000; 81:2519-2523.
144. Park EK, Soh BY, Jang YS, Park JH, Chung GH. Immune induction and modulation in mice following immunization with DNA encoding F protein of respiratory syncytial virus. Mol Cells 2001; 12:50-56.
145. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, Tristram DA, Siber GR, Prince GA, Van Raden M, Hemming VG, The Respiratory Syncytial Virus Immune Globulin Study Group. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993; 329:1524-1530.
146. Ottolini MG, Hemming VG. Prevention and treatment recommendations for respiratory syncytial virus infection-background and clinical experience 40 years after discovery. Drugs 1997; 54:867-884.
147. Hayes C, Wilkerson S, Bibb K, Schuschke L, Guest A. Effectiveness of RSVIVIG in premature infants: success in the home. Pediatrics 1999; 103:698-699.
148. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99:93-99.
149. Thakur BK, Wu LR, Schaeufele JF. RSV-IGIV therapy: a cost/benefit analysis. Pediatrics 1997; 100:417-417.
150. Barton LL, Grant KL, Lemen RJ. Respiratory syncytial virus immune globulin: decisions and cost. Pediatr Pulmonol 2001; 32:20-28.
151. Russell A. Palivizumab: an overview. Hosp Med 1999; 60:873-877.
152. Null D, Bimle C, Weisman L, Johnson K, Steichen J, Singh S, Wang E, Asztalos E, Loeffler AM, Azimi PH, Lieberman JM, ODonnell NE, Cooke RJ, McCormick K, Koo W, Hammami M, Milner AD, Gaon P, Nachman S, Tarpey KP, Sanchez PJ, Broyles RS, Bratcher D, Ball MV, Duda FJ, DeCuir PM, Pollara B, Nelson LS, Balbus M, Schultz MJ, Chipps BE, Givner LB, OShea M, Everard M, Pfeffer K, Page AJ, Dennehy PH, Modlin J, Rhodes T, DeVincenzo N, Nickerson B, Arrieta A, Boucher FD, Keeney RE, Young TE, Stevens JC, Ariagno R, Adams M, Polak MJ. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-537.
153. Lenney W. Palivizumab and RSV prevention. Arch Dis Child 2000; 83):87.
154. American Academy of Pediatrics Committee on Infectious Diseases CoFaN. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGV. Pediatrics 2001; 102:1211-1216.
155. Englund JA, Glezen WP. Passive immunization for the prevention of otitis media. Vaccine 2000; 19:S116-S121.
156. Brunvand L, Lindemann R, Grogaard J. Who shall not receive palivizumab? Pediatrics 2000; 106):866.
157. Hashmi NA, Cosgrove JV, MacMahon P. Prophylaxis in RSV infection. Palivizumab-is it worthwhile? Irish Med J 2000; 93):284.
158. Greenough A. Recent advances in the management and prophylaxis of respiratory syncytial virus infection. Acta Paediatr 2001; 90:11-14.
159. Declercq E. Perspectives for the chemotherapy of respiratory syncytial virus RSV infections. Int J Antimicrob Agents 1996; 7:193-202.
160. Committee on Infectious Diseases. Use of ribavirin in the treatment of respiratory syncytial virus in infection. Pediatrics 1993; 92:501-504.
161. Huffman JH, Sidwell RW, Khare GP, Witkowski JT, Allen LB, Robbins RK. In vitro effect of 1-b-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide Virazole, ICN 1229 on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother 1973; 3:235-241.
162. Hruska JF, Morrow PE, Suffin SC, Douglas RG. In vivo inhibition of respiratory syncytial virus by ribavirin. Antimicrob Agents Chemother 1982; 21:125-130.
163. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, Ten Eyck LG, Hall WJ. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infections. N Engl J Med 1983; 308:1443-1447.
164. Taber LH, Knight V, Gilbert BE, McClung HW, Wilson SZ, Norton HJ, Thurston JM, Gordon WH, Atmar RL, Schlaudt WR. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 1983; 72:613-618.
165. Hall CB, McBride JT, Gala CL, Hildreth SW, Schnabel KC. Ribavirin treatment of respiratory syncytial virus infection in infants with underlying cardiopulmonary disease. J Am Med Assoc 1985; 254:3047-3051. Respiratory Syncytial Virus 131
166. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12:1139-1146.
167. De Clercq E, Cools M, Balzarini J, Snoeck R, Andrei G, Hosoya M, Shigeta S, Ueda T, Minakawa N, Matsuda A. Antiviral activities of 5-ethynyl-1-b-Dribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob Agents Chemother 1991; 35:679-684.
168. Eriksson B, Helgstrand E, Johansson NG, Larsson A, Misiorny A, Noren JO, Philipson L, Stenberg K, Stening G, Stridh S, Oberg B. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 1977; 11:946-951.
169. Wray SK, Gilbert BE, Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res 1985; 5:39-48.
170. Connor J. Ribavirin pharmacokinetics. Pediatr Infect Dis J 1990; 9:S91-S92.
171. Christenson AR, Petersen F, Beatty P. Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV. Bone Marrow Transplant 1999; 24:661-664.
172. Whimbey E, Champlin RE, Couch RB, Englund JA, Goddrich JM, Raad I, Przepiorka D, Lewis VA, Mirza N, Yousu H, Tarrand JJ, Bodey GP. Community respiratory virus infection among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996; 22:778-782.
173. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation-a compassionate use experience. Bone Marrow Transplant 2000; 25:161-165.
174. Bradley JS, Conner JD, Campogiannis LM. Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus infection. Antimicrob Agents Chemother 1990; 34:68-70.
175. Kilham L, Ferm VH. Congenital anomalies induced in hamster embryos with ribavirin. Science 1977; 195:413-414.
176. Fernandez H, Banks G, Smith R. Ribavirin: a clinical overview. Eur J Epidemiol 1986; 2:1-14.
177. Moler FW, Steinhart CM, Ohmit SE, Stidham GL for the Pediatric Critical Care Group. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. J Pediatr 1996; 128:422-428.
178. Marquardt ED. Cost of ribavirin therapy for respiratory syncytial virus infection. J Pediatr 1995; 126):847.
179. Wyde PR, Moore-Poveda DK, De Clercq E, Neyts J, Matsuda A, Minakawa N, Guzman E, Gilbert BE. Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections. Antimicrob Agents Chemother 2000; 44:1146-1152.
180. Kawana F, Shigeta S, Hosoya M, Suzuki H, De Clercq E. Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro. Antimicrob Agents Chemother 1987; 31:1225-1230.
181. Kosugi Y, Saito Y, Mori S, Watanabe J, Baba M, Shigeta S. Antiviral activities of mizoribine and other inosine monophosphate dehydrogenase inhibitors against several ortho- and paramyxoviruses. Antiviral Chem Chemother 1994; 5:366-371.
182. Wyde PR, Ambrose MW, Meyer HL, Gilbert BE. Toxicity and antiviral activity of LY253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res 1990; 14:237-247.
183. Markland W, McQuaid TJ, Jain J, Kwong AD. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother 2000; 44:859-866.
184. Shigeta S, Mori S, Baba M, Ito M, Honzumi K, Nakamura K, Oshitani H, Numazaki Y, Matsuda A, Obara T, Shuto S, De Clercq E. Antiviral activities of ribavirin, 5-ethynyl-1-b-D-ribofuranosylimidazole-4-carboxamide, and 6'-R-6'-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob Agents Chemother 1992; 36:435-439.
185. Wyde PR, Ambrose MW, Meyer HL, Zolinski CL, Gilbert BE. Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res 1990; 14:215-226.
186. Shuto S, Obara T, Toriya M, Hosoya M, Snoeck R, Andrei G, Balzarini J, De Clercq E. New neplanocin analogue. 1. Synthesis of 6'-modified neplanocin A derivatives as broad-spectrum antiviral agents. J Med Chem 1992; 35:324-331.
187. Wyde PR, Gilbert BE, Ambrose MW. Comparison of the anti-respiratory syncytial virus activity and toxicity of papaverine hydrochloride and pyrazofurin in vitro and in vivo. Antiviral Res 1989; 11:15-26.
188. Wyde PR, Moore DK, Pimentel DM, Blough HA. Evaluation of the antiviral activity of N-phosphonoacetyl-L-aspartate PALA against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats. Antiviral Res 1995; 27:59-69.
189. De Clercq E, Murase J, Marquez VE. Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem Pharmacol 1991; 41:1821-1829.
190. Siddiqi SM, Chen X, Schneller SW. Antiviral enantiomeric preference for 5'- noraristeromycin. J Med Chem 1994; 37:551-554.
191. Siddiqi SM, Chen X, Rao J, Schneller SW. 3-Deaza- and 7-deaza-5'- noraristeromycin and their antiviral properties. J Med Chem 1995; 38:1035-1038.
192. Woods JM, Marr CLP, Penn CR. Inhibition of respiratory syncytial virus replication in vitro by a pyrazole dicarboxamide analogue of ribavirin. Antiviral Chem Chemother 1994; 5:340-343.
193. De Clercq E. Antiviral activity spectrum and target of action of different classes of nucleoside analogues. Nucleosides Nucleotides 1994; 13:1271-1295.
194. The Wellcome FDN. Patent EP-4179990-B, 1996.
195. Barnard DL, Sidwell RW, Xiao W, Player MR, Adah SA, Torrence PF. 2-5ADNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection. Antiviral Res 1999; 41:119-134.
196. Jairath S, Vargas PB, Hamlin HA, Field AK, Kilkuskie RE. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res 1997; 33:201-213.
197. Aulabaugh A, Ding W-D, Ellestad G, Gazumayan A, Hess CD, Krishnamurthy G, et al. Inhibition of respiratory syncytial virus by a new class of chemotherapeutic agents. Drugs Future 2000; 25:287-294.
198. Feldman SA, Audet S, Beeler JA. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparin sulfate. J Virol 2000; 74: 6442-6447.
199. Krusat T, Streckert HJ. Heparin-dependent attachment of respiratory syncytial virus RSV to host cells. Arch Virol 1997; 142:1247-1254.
200. Bourgeois C, Bour JB, Lidholt K, Gauthray C, Pothier P. Heparin-like structures on respiratory syncytial virus are involved in its infectivity in vitro. J Virol 1998; 72:7221-7227.
201. Neyts J, Reymen D, Letourneur D, Jozefonvicz J, Schols D, Este J, Andrei G, McKenna P, Witvrouw M, Ideda S, et al. Differential antiviral activity of derivatized dextrans. Biochem Pharmacol 1995; 50:743-751.
202. Hasui M, Matsude M, Okutani K, Shigeta S. In vitro antiviral activities of sulfated polysaccharides from a marine microalga Cochlodinium polykritoides against human immunodeficiency virus and other enveloped viruses. Int J Biol Macromol 1995; 17:293-297.
203. Barnard DL, Hill CL, Gage T, Matheson JE, Huffman JH, Sidwell RW, Otto MI, Schinazi RF. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Antiviral Res 1997; 34:27-37.
204. Shigeta S, Mori S, Watanabe J, Baba M, Khenkin AM, Hill CL, Schinazi RF. In vitro anti-myxovirus and anti-human immunodeficiency virus activities of polyoxometalates. Antiviral Chem Chemother 1995; 6:114-122.
205. Collins PL, Mottet G. Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 1991; 72:3095-3101.
206. Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr. Peptides from conserved regions of paramyxovirus fusion F proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci USA 1996; 93:2186-2191.
207. McKimm-Breschkin J. VP-14637 ViroPharma. Curr Opin Invest Drugs 2000; 1:425-427.
208. Gazumyan A, Mitsner B, Ellestad GA. Novel anti-RSV dianionic dendrimer-like compounds: design, synthesis and biological evaluation. Curr Pharm Design 2000; 6:525-546.
209. Ding WD, Mitsner B, Krishnamurthy G, Aulabaugh A, Hess CD, Zaccardi J, Cutler M, Feld B, Gazumyan A, Raifeld Y, Nikitenko A, Lang SA, Gluzman Y, OHara B, Ellestad GA. Novel and specific respiratory syncytial virus inhibitors that target virus fusion. J Med Chem 1998; 41:2671-2675.
210. Wyde PR, Moore-Poveda DK, O’Hara B, Ding W-D, Mitsner B, Gilbert BE. CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antiviral Res 1998; 38:31-42.
211. Nikitenko AA, Raifeld YE, Wang TZ. The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus. Bioorg Med Chem Lett 2001; 11:1041-1044.
212. Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 1998; 177:1458-1464.
213. University of California, Berkely. Patent WO9810764, 1998.
214. Watanabe W, Sudo K, Sato R, Kajiyashiki T, Konno K, Shigeta S, Yokota T. Novel anti-respiratory syncytial RS viral compounds: benzodithiin derivatives. Biochem Biophys Res Commun 1998; 249:922-926.
215. Kimura K, Mori S, Tomita K, Ohno K, Takahashi K, Shigeta S, Terada M. Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo. Antivir Res 2000; 47:41-51.
216. Pastey MK, Gower TL, Spearman PW, Crowe JE, Graham BS. A RhoAderived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nature Med 2000; 6:35-40.
217. Vanderbilt University. Patents WO9962932 and WO9839287, 1999.
218. Gower TL, Graham BS. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicob Agents Chemother 2001; 45:1231-1237.
219. Glatthaar-Saalmuller B, Sacher F, Esperester A. Antiviral activity of an extract derived from roots of Eleutherococcus senticosus. Antiviral Res 2001; 50:223-228.
220. Chen JL, Blanc P, Stoddart CA, Bogan M, Rozhon EJ, Parkinson N, Ye Z, Cooper R, Balick M, Nanakorn W, Kernan MR. New iridoids from the medicinal plant Barleria prionitis with potent activity against respiratory syncytial virus. J Nat Prod 1998; 61:1295-1297.
221. Sakai S, Kawamata H, Kogure T, Mantani N, Terasawa K, Umatake M, Ochiai H. Inhibitory effect of ferulic acid and isoferulic acid on the production of macrophage inflammatory protein-2 in response to respiratory syncytial virus infection in RAW264.7 cells. Mediators Inflamm 1999; 8:173-175.
222. Piraino F, Brandt CR. Isolation and partial characterization of an antiviral, RC-183, from the edible mushroom Rozites caperate. Antiviral Res 1999; 43:67-78.
223. Kott V, Barbini L, Cruanes M, Munoz JD, Vivot E, Cruanes J, Martino V, Ferraro G, Cavallaro L, Campos R. Antiviral activity in Argentine medicinal plants. J Ethnopharm 1999; 64:79-84.
224. Chiba T, Shigeta S, Numazaki Y. Inhibitory effect of pyridobenzazoles on virus replication in vitro. Biol Pharm Bull 1995; 18:1081-1083.
225. G.D. Searle and Co. Patent WO 9522975, 1995.
226. Chiba T, Shigeta S, Numazaki Y. Inhibitory effect of pyridobenzazoles on virus replication in vitro. Biol Pharm Bull 1995; 18:1081-1083.
227. Trimeris, Inc. Patent WO 9839287, 1998.
228. Viropharma I. Patent WO 9938508, 1999.
229. Kumar M, Behera AK, Matsuse H, Lockey RF, Mohapatra SS. Intranasal IFN-gamma gene transfer protects BALB/c mice against respiratory syncytial virus infection. Vaccine 1999; 18:558-567.
230. van Schaik SM, Obot N, Enhorning G, Hintz K, Gross K, Hancock GE, Stack AM, Welliver RC. Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice. J Med Virol 2000; 62:257-266.
231. Spender LC, Hussell T, Openshaw PJM. Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease. J Gen Virol 1998; 79:1751-1758.
232. Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM, Brus F, Draaisma JM, Pekelharing-Berghuis M, van Diemen-Steenvoorde RA, Kimpen JL. Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. J Infect Dis 2001; 184:355-358.
233. Aberle JH, Aberle SW, Dworzak MN, Mandl CW, Rebhandl W, Vollnhofer G, Kundi M, Popow-Kraupp T. Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease. Am J Respir Crit Care Med 1999; 160:1263-1268.
234. Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM, Brus F, Draaisma JT, Geelen SM, van Vught HJ, Kimpen JL. Peripheral blood cytokine responses and disease severity in respiratory syncytial virus bronchiolitis. Eur Respir J 1999; 14:144-149.
235. Chipps BE, Sullivan WF, Portnoy JM. Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus. Pediatr Infect Dis J 1993; 12:653-658.
236. Sung RYT, Yin J, Oppenheimer SJ, Tam JS, Lau J. Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a. Arch Dis Child 1993; 69:440-442.
237. Higgins PG, Barrow GI, Tyrell DAJ, Isaacs D, Gauci CL. The efficacy of intranasal interferon a-2a in respiratory syncytial virus infection in volunteers. Antiviral Res 1990; 14:3-10.
238. Dai J-X. Children’s respiratory viral diseases treated with interferon aerosol. Am Rev Respir Dis 1990; 141:A606.
239. vanWoensel J, Kimpen J. Therapy for respiratory tract infections caused by respiratory syncytial virus. Eur J Pediatr 2000; 159:391-398.
240. Kneyber MCJ, Moll HA, deGroot R. Treatment and prevention of respiratory syncytial virus infection. Eur J Pediatr 2000; 159:399-411.
241. Prince GA. An update on respiratory syncytial virus antiviral agents. Expert Opin Invest Drugs 2001; 10:297-308.
242. Quinlan KP, Hayani KC. Vitamin A and respiratory syncytial virus infection. Arch Paediatr Adolesc Med 1996; 150:25-30.
243. Pinnock CB, Douglas RM, Marin AJ, Badcock NR. Vitamin A status of children with a history of respiratory syncytial virus infection in infancy. Aust Pediatr J 1988; 24:286-289.
244. Lamb RA and Kolakofsky D. Paramyxoviridae: the viruses and their replication. In Fields B, Knipe DM, Chanock RM, Hirsch MS, Melnick JL, Monath TP, Roizman B, eds. Fields Virology. New York: Raven Press. 1996:1191.